Vaccine immunotherapy for prostate cancer: from mice to men.

about

Oncolytic adenovirus-mediated therapy for prostate cancer Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.Improving adenoviral vectors and strategies for prostate cancer gene therapy

P2860

Q27004796-0ABF774F-D0C6-4BD6-887C-C18AE3541705 Q38760061-98866E12-F7DC-4B4D-A90D-C06CB5EA787F Q58801177-3F9D6B47-504C-4296-BD88-6AC374E6CB59

P2860

Vaccine immunotherapy for prostate cancer: from mice to men.

Item

http://www.wikidata.org/entity/Q42217435

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Vaccine immunotherapy for prostate cancer: from mice to men.

@en

Vaccine immunotherapy for prostate cancer: from mice to men.

@nl

type

Item

label

Vaccine immunotherapy for prostate cancer: from mice to men.

@en

Vaccine immunotherapy for prostate cancer: from mice to men.

@nl

prefLabel

Vaccine immunotherapy for prostate cancer: from mice to men.

@en

Vaccine immunotherapy for prostate cancer: from mice to men.

@nl

P1476

Vaccine immunotherapy for prostate cancer: from mice to men.

@en

P2093

Ambika Kattula

http://www.w3.org/2001/XMLSchema#string

Daniel Vaena

http://www.w3.org/2001/XMLSchema#string

David M Lubaroff

http://www.w3.org/2001/XMLSchema#string

Erica Brown

http://www.w3.org/2001/XMLSchema#string

James A Brown

http://www.w3.org/2001/XMLSchema#string

Julie Eastman

http://www.w3.org/2001/XMLSchema#string

Karen C Griffith

http://www.w3.org/2001/XMLSchema#string

Pamela Zehr

http://www.w3.org/2001/XMLSchema#string

Richard D Williams

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2014

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer.

Activation of thymic regeneration in mice and humans following androgen blockade.

Guideline for the management of clinically localized prostate cancer: 2007 update.

The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system.

Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN

Clinical evaluation of TRICOM vector therapeutic cancer vaccines

P2888

s12026-014-8531-2

P304

229-235

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12026-014-8531-2

http://www.w3.org/2001/XMLSchema#string

P433

1-3

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth G Nepple

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1007914090

http://www.w3.org/2001/XMLSchema#string

P698

24847764

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

Vaccine immunotherapy for prostate cancer: from mice to men.

about

P2860

P2860

Vaccine immunotherapy for prostate cancer: from mice to men.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921